< Previous30FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Overview Saturday, 23 April 2022 Hall AHall BHall CHall DHall EHall F 08:30 – 11:3008:30 – 10:3008:30 – 10:3008:30 – 10:30 EW006OS011SY001EW007 EUCAST Educational Workshop New insights on typing: viewing the genome above and below the infra red spectrum Infections in patients receiving new immunomodulatory therapies Advances in Clostridioides difficile infection outbreak prevention and control 11:00 – 12:0011:00 – 12:0011:00 – 12:0011:00 – 12:00 SY015OS020SY016OS021 Young Investigator Award for Research in CM and ID Novel insights into herpetic infections COVID-19 beyond the clinic: the importance of public engagement Digital health applications for CM/ ID 13:30 – 14:3013:30 – 15:3013:30 – 14:3013:30 – 14:30 KN032SY033SY034OS038 The dark side of Gram-negative respi- ratory infections in the ICU Clinical aspects of HIV infection Clinical research in infectious endocarditis: past, present, and future Year in Clinical Microbiology 14:45 - 15:4514:45 - 15:4514:45 - 15:4514:45 - 15:45 KN043OS047SY044SY045 Pathogens and the microbiome: antibiotics at the crossroads A post-COVID syndrome: a never- ending story Respiratory viral infections in hospital settings One Health and mycology: what are thesignificantand potential interactions between agriculture and human health? All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. 13:00 – 16:00 TAE Day TAE Day 16:15 – 18:1516:15 – 18:1516:15 – 18:1516:15 – 18:15 EW052OS057SY051EW053 Digging in the molec- ular epidemiology of MDR Enterobacte- rales Opportunistic infec- tions of the central nervous system COVID-19 vaccination of special populations: protecting the vulnerable Molecular-guided therapy for sexually transmitted infections ID ID ID IDID ID CM CM CM CM CM IC IC PH PH PHScientific Programme 31FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Hall GHall HHall IHall JHall KHall L 08:30 – 10:3008:30 – 10:3008:30 – 10:3008:30 – 10:3008:30 – 10:3008:30 – 10:30 SY002EW008SY003OS012OS013SY004 Fungal infections from head to toes New perspectives on Schistosomiasis in Europe Genomics underpin the clinical and public health management of tuberculosis COVID-19 diagnostics: new and newer Advances in prevention of urinary catheter and central lineassociated bloodstream infections Challenges and opportunities in CM/ID training and practice 11:00 – 12:0011:00 – 12:0011:00 – 12:0011:00 – 12:0011:00 – 12:0011:00 – 12:00 OS022OS023SY017ME018ME019OF025 Rapid diagnostic tools inform prudent antibiotic use New Insights about PK/PD of antifungal agents Pathogenic Escherich- ia coli: the emergence of crosspathotypes from the genomic continuum Interactive paediatric cases How to apply Digital PCR in clinical microbiology Innovative preclinical PK/PD studies All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Colour Key Educational Workshops, Meet-the-Expert Sessions Sessions specifically interesting for: Infectious Disease specialists Symposia (1h/2h)Oral sessions (1h/2h) Keynote Lectures Clinical Microbiologists Infection Control specialistsPublic Health specialists CM IDIC Open Forum & Virtual Walk ThroughsTAE Day PH Integrated Symposia & Pipeline Corners are not detailed in this book. Please refer to the Industry Guide for session details. 12:15 - 13:15 IS01 The lab in the future: how COVID-19 taught us the value of a tran- scendent laboratory service? 13:30 – 14:3013:30 – 14:3013:30 – 15:3013:30 – 15:3013:30 – 14:3013:30 – 15:00 SY035OS039EW037SY036OS040IS06 Exploring the urinary microbiome: facts, figuresandtherapeu- tic potential New mechanisms of antifungal resistance in emerging yeast pathogens Getting your CM/ID paper published Making decisions on antibiotic therapy in difficultsituations Ever challenging malaria Role of monoclonal antibodies (mAbs) in the evolution of COVID-19 treatment 14:45 - 15:4514:45 - 15:4514:45 - 15:45 SY046OF049OS048 Should you manage bloodstream infec- tion differently in immunocompromised patients? Targets for antimicro- bial stewardship Modelling host- pathogen interaction in persistent infections 16:15 – 18:1516:15 – 18:1516:15 – 18:1516:15 – 18:15 OS058EW054EW055IS09 What is new in nocar- diosis? Best of both worlds: maximising serotype coverageandquality of immune responses for pneumococcal disease prevention Current treatment approach to COVID-19 Should economical aspects be considered for CM/ID/ ICP guidelines? IDID ID ID ID ID ID ID CM CM CM CM CM CM PH PH32FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Overview Saturday, 23 April 2022 All times are specified in WEST (UTC +1). If attending online, please convert to your local timezone. Hall MHall NHall OHall PHall Q 08:30 – 10:3008:30 – 10:3008:30 – 10:3008:30 – 10:30 EW009OS014SY005EW010 Soft tissue, bone and joint infections: a treatment update New insights into phages: current challenges and future developments Understanding COVID-19 lung disease Novel predictive and diagnostic tools in severe viral and bacterial infections 11:00 – 12:0011:00 – 12:0011:00 – 12:0011:00 – 12:00 OS024OF026OF027OF028 COVID-19 in special populations Treatment of XDR bacteria: highway to hell Mechanistic insights into host responses to important pathogens COVID-19 treatment insights and advances 12:15 - 13:1512:15 - 13:1512:15 - 13:1512:15 - 13:15 IS02IS03IS04IS05 Protecting vulnerable pop- ulations from COVID-19 Sample self-collection, a lesson gained during the COVID pandemic A spotlight on antibiotic resistance in community settings: uncomplicated urinary tract infections Leveraging the host re- sponse to acute infection to create new diagnostic and prognostic tools 13:30 - 14:3013:30 - 15:3013:30 - 15:3013:30 - 15:30 OS041IS34IS07IS08 mRNA science: a paradigm shift to address unmet medical needs Building on a strong foun- dation to address a new era to help protect against pneumococcal disease COVID-19 vaccines: lessons learnt and prospects in 2022 Novel approaches to antimicrobial susceptibility testing 16:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:1516:15 - 18:15 IS10EW056IS11IS12IS13 Thequestforreliable biofilmmodels:howto narrow the gap to clinical implementation? Changing microbiology: focus to critical infectious diseases by state-of-art technologies Expected impact on clinical outcomes of earlyidentificationand early management of MDR Gram-negative infections The usefulness of various point-of-care tests against evolving COVID-19 MDR Gram-negative infections in a pandemic world: contemporary treatment options IDIDID CMScientific Programme 33FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 ESCMID WHO Observership Visit the WHO Regional Office for Europe! A group of 10 observers(ESCMID members) will undertake a two-day observershipprogramme at the WHORegional Office for Europe, Division of Health Emergencies and Communicable Diseases(DEC) in Copenhagen, Denmark. The next application period for this two-day visit will be announced via the ESCMID website as well as the ESCMID social media channels. w ww.euro.who.int Arena 1 & 2 Session TimeSessionArena 11:00 - 12:00VW029Virtual Walk ThroughHotchpotch of RTI2 12:15 - 13:15FO031Open ForumEthical issues in infectious diseases1 13:30 - 14:30VW042Virtual Walk ThroughUnder the hood: mechanisms of action of new antibacterial agents2 14:45 - 15:45VW050Virtual Walk ThroughWise use of bioinformatics to study diversity and transmission in endemic and outbreak settings 1 Colour Key Educational Workshops, Meet-the-Expert Sessions Sessions specifically interesting for: Infectious Disease specialists Symposia (1h/2h)Oral sessions (1h/2h) Keynote Lectures Clinical Microbiologists Infection Control specialistsPublic Health specialists CM IDIC Open Forum & Virtual Walk Throughs PH Integrated Symposia & Pipeline Corners are not detailed in this book. Please refer to the Industry Guide for session details.34FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Scientific Programme Saturday, 23 April 2022 ID SY00108:30 - 10:30Hall C Symposium Infections in patients receiving new immunomodulatory therapies ChairsOliver A. Cornely (Cologne, Germany) Carlota Gudiol (Barcelona, Spain) S000108:30Patients receiving immune check-point inhibitors Gil Redelman-Sidi (New York, United States) S000209:00Patients receiving CAR-T therapy Andrea Henden (Herston, Australia) S000309:30Non-neutropenic infection associated risk in patients with haematological malignancies Monica Slavin (Melbourne, Australia) S000410:00Patients receiving therapy for systemic or organ- specific autoimmune diseases Mario Fernandez Ruiz (Madrid, Spain) ID SY00208:30 - 10:30Hall G Symposium Fungal infections from head to toe ChairsAnuradha Chowdhary (Delhi, India) Emmanuel Roilides (Thessaloniki, Greece) S000508:30Emerging treatment failure in dermatophytosis: genotyping and resistance testing of the Trichophyton mentagrophytes species complex Philipp Bosshard (Zurich, Switzerland) S000609:00Update on Tinea capitis: epidemiology, symptoms and treatment Pietro Nenoff (Mölbis, Germany) S000709:30Update on diagnosis and treatment of recurrent vulvovaginal candidiasis Riina Richardson (Manchester, United Kingdom) S000810:00The role of Malassezia in health and disease Ditte Marie Lindhardt Saunte (Roskilde, Denmark) Co-organised with: ESCMID Fungal Infection Study Group (EFISG) PH SY00308:30 - 10:30Hall I Symposium Genomics underpin the clinical and public health management of tuberculosis ChairsSebastien Gagneux (Basel, Switzerland) Robyn Lee (Toronto, Canada) S000908:30Understanding TB pathogenicity and host interactions using genomic approaches Stefan Niemann (Borstel, Germany) S001009:00Genomics in the diagnosis of drug resistance in TB Paolo Miotto (Milano, Italy) S001109:30Integrating genomics into TB management in an African setting Yonas Kassahun (Addis Ababa, Ethiopia) S001210:00New tools for genomic prediction and mapping of resistance in TB Timothy Walker (Ho Chi Minh City, Vietnam) ID CM SY00408:30 - 10:30Hall L Symposium Challenges and opportunities in CM/ID training and practice ChairsEmmanuelle Cambau (Paris, France) Valentijn Schweitzer (Utrecht, Netherlands) S001308:30How to excel and become a leader in CM, ID or IC? Truls Michael Leegaard (Lørenskog, Norway) S001409:00Developing effective communication skills: social media and networking Muge Cevik (Edinburgh, United Kingdom) S001509:30Practising Clinical Microbiology in low-resource settings Makeda Semret (Montreal, Canada) S001610:00Practising Infectious Diseases in low-resource settings Sipho Kenneth Dlamini (Cape Town, South Africa) Co-organised with: ESCMID Professional Affairs Subcommittee (PAS), Trainee Association of ESCMID (TAE) Presentations in light grey were not registered at the time of publishing.Scientific Programme 35FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 ID SY00508:30 - 10:30Hall P Symposium New insights into phages: current challenges and future developments ChairsJoana Azeredo (Braga, Portugal) Jean-Paul Pirnay (Brussels, Belgium) S001708:30Preparation standards for personalised phage therapy Kiljunen Saija (Helsinki, Finland) S001809:00Immune responses and phage: how phage pharmacokinetics is shaped by immunological factors Krystyna Dabrowska (Warsaw, Poland) S001909:30Clinical trials with phages: design challenges and regulatory issues Shawna Mccallin (Schlieren, Switzerland) S002010:00Clinical evidence for the efficacy of phages (so far) Tristan Ferry (Lyon, France) Co-organised with: ESCMID Study Group for Non- traditional Antibacterial Therapy (ESGNTA) CM EW00608:30 - 11:30Hall A Educational Workshop EUCAST Educational Workshop ChairsAlasdair P. MacGowan (Bristol, United Kingdom) Arjana Tambic Andrasevic (Zagreb, Croatia) W002108:30EUCAST Update Christian Giske (Stockholm, Sweden) W002209:00Putting certainty into antimicrobial susceptibility testing Gunnar Kahlmeter (Växjö, Sweden) W002309:30PK/PD breakpoints in the EUCAST breakpoint tables Shampa Das (Liverpool, United Kingdom) W002410:00Revising aminopenicillin breakpoints John D. Turnidge (Hawthorn, Australia) W002510:30Screening and testing for antifungal resistance Maiken Arendrup (Copenhagen, Denmark) Co-organised with: EUCAST Steering Committee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) IC EW00708:30 - 10:30Hall E Educational Workshop Advances in Clostridioides difficile infection outbreak prevention and control ChairsSarah Tschudin Sutter (Basel, Switzerland) Lutz Von Müller (Coesfeld, Germany) W002608:30Is there a role for ribotyping in the WGS era? Windy Tanner (New Haven, United States) W002709:00Any Clostridium lurking in your patient room? The role of the community environment in C. difficile outbreaks Sandra Janezic (Maribor, Slovenia) W002809:30Going with the FLO: frontline ownership is crucial for C. difficile outbreak prevention and management Gianluca Ianiro (Rome, Italy) Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD), ESCMID Study Group for Nosocomial Infections (ESGNI) PH EW00808:30 - 10:30Hall H Educational Workshop New perspectives on schistosomiasis in Europe ChairsAndreas Neumayr (Basel, Switzerland) Lisette Van Lieshout (Leiden, Netherlands) W002908:30Gaps in managing schistosomaisis in Europe Eyrun Kjetland (Oslo, Norway) W003009:00One Health perspective on schistosomiasis: prevalence and distribution of schistosomiasis in a multi-host system Joanne Webster (Hatfield, United Kingdom) W003109:30The toolkit for diagnosis and morbidity assessment of schistosomiasis: lab and beyond Francesca Tamarozzi (Negrar, Italy) Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP) ID EW00908:30 - 10:30Hall M Educational Workshop Novel predictive and diagnostic tools in severe viral and bacterial infections ChairsBarbara C. Kahl (Münster, Germany) Mi-Na Kim (Seoul, Korea, Republic of) W003208:30Living colours of infection and inflammation Olivier Gheysens (Leuven, Belgium) Saturday, 23 April 202236FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 W003309:00Hypercytokinaemia in critically ill COVID-19 as indicator of cell death and secondary bacterial infections Srikanth Mairpady Shambat (Zurich, Switzerland) W003409:30Specific clinical phenotypes of necrotising soft- tissue infection predicted by discriminatory biomarker signatures Anna Norrby-Teglund (Stockholm, Sweden) ID EW01008:30 - 10:30Hall Q Educational Workshop Understanding COVID-19 lung disease ChairsAdrian John Brink (Cape Town, South Africa) Veroniek Saegeman (Sint-Niklaas, Belgium) W003508:30Infectious disease and public health perspective Raquel Duarte (Porto, Portugal) W003609:00ICU perspective Sascha David (Zurich, Switzerland) W003709:30Pathologist`s perspective Domitille Callon (Reims, France) Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF), Spanish Society of Pathologists (SEAP) OS01108:30 - 10:30Hall B 2-Hour Oral Session New insights on typing: viewing the genome above and below the infrared spectrum ChairsNatacha Couto (Bath, United Kingdom) Mario Ramirez (Lisbon, Portugal) O0038Early identification of an outbreak involving OXA-48 producing Klebsiella pneumoniae using Fourier transform infrared (FT-IR) spectroscopy typing C. Pitart* (Barcelona, Spain), Y. Zboromyrska, J. Bosch, E. Rubio, M. Piquet, B. Torralbo, I. Fortes, S. Valls, L. Rodriguez, G. Santana, A. Del Río, J.A. Martinez, A. Vilella, A. Soriano, C. Casals-Pascual, I. Roca, J. Vila O0039Development and evaluation of a new typing system for Treponema pallidum F. González-Candelas* (Paterna, Spain), M. Diaz-Pla, P. Pospíšilová, D. Šmajs, T. Kawahata, P.P. Bosshard, K. Nieselt, N. Arora, L. Giacani O0040Comparison of a novel whole genome multilocus sequence typing (wgMLST) schema forStreptococcus pyogeneswith other typing methods A. Friães* (Lisbon, Portugal), R. Mamede, M. Ferreira, J. Melo-Cristino, M. Ramirez O0041Turning ATR FT-IR spectroscopy into an easy, quick and reproducibleKlebsiella pneumoniae typing method Â. Novais* (Porto, Portugal), A.B. Gonçalves, T.G. Ribeiro, A.R. Freitas, G. Mendéz, L. Mancera, A. Read, V. Alves, L. López-Cerero, J. Rodríguez- Baño, Á. Pascual, L. Peixe O0042Rapid Clostridiodes difficileribotyping based on MALDI-TOF MS and machine learning A. Candela* (A Coruña, Spain), D. Rodriguez-Temporal, M.J. Arroyo, M. Marin, A. Martin, L. Jimenez-Navarro, L. Alcala, G. Mendez, P. Muñoz, L. Mancera, B. Rodriguez-Sanchez O0043Evaluation of Fourier-tansform infrared spectroscopy as a typing method for vancomycin-resistant Enterococcus faeciumisolates J. Liese* (Tübingen, Germany), S. Wolf, F. Melcharick, B. Bader, S. Peter O0044Escherichia marmotae: ayet unrecognised Escherichia species and its impact for zoonotic and antimicrobial resistance transmission U. Binsker* (Berlin, Germany), A.K. Gadicherla, A. Käsbohrer, J.A. Hammerl O0045Phylogenomics of Pseudomonas aeruginosa isolated from mechanically ventilated patients in European intensive care units M. Berkell* (Antwerp, Belgium), T.E. Van Der Schalk, D.E. Tabor, B.B. Xavier, C. Recanatini, L. Timbermont, P. Tedder, C. Lammens, A. Digiandomenico, B. François, H. Jafari, J. Kluytmans, A. Ruzin, J. Chastre, H. Goossens, M.T. Esser, S. Malhotra-Kumar O0046Validation of an optimised whole genome sequencing workflow for the detection of virulence factors and resistance to methicillinof Staphylococcus aureus strains in a national reference laboratory C. Kolenda* (Lyon, France), P. Martins-Simoes, C. Dupieux-Chabert, A.G. Ranc, B. Youenou, L. Beraud, C. Ginevra, E. Jeanne, F. Laurent, F. Vandenesch, A. Tristan O0047Within host genetic variation in Neisseria gonorrhoeae over the course of infection J. De Korne-Elenbaas* (Amsterdam, Netherlands), S.M. Bruisten, H.C.J. De Vries, A.P. Van Dam OS01208:30 - 10:30Hall J 2-Hour Oral Session COVID-19 diagnostics: new and newer ChairsPetar Velikov (Sofia, Bulgaria) Snjezana Zidovec Lepej (Zagreb, Croatia) O0048Is an increasing occurrence of SARS-CoV-2 N gene dropout variants in a frequently employed multiplex RT-PCR assay indicating a selection advantage of a new variant? D.F. Hilti* (Buchs, Switzerland), F. Wehrli, A. Roditscheff, M. Risch, F. Rudolf, L. Lorenz, A. Egli, T. Bodmer, N. Wohlwend Saturday, 23 April 2022Scientific Programme 37FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 O0049Performance of self-testing with SARS-CoV-2 antigen rapid diagnostic test in healthcare workers: a multi-centre study V. Zwart* (Breda, Netherlands), N. Van Der Moeren, J.L. Murk, J. Stohr, J. Kluytmans, W. Van Den Bijllaardt O0050Use of artificial intelligence on rapid COVID-19 diagnosis using real-time polymerase chain reaction data B. Baddal* (Nicosia, Cyprus), T. Sanlidag, E. Özbilge O0051SARS-CoV-2 detection in saliva samples from children using RT-PCR assays: a systematic review and meta-analysis of accuracy G. Menchinelli* (Rome, Italy), G. De Angelis, A. Grossi, B. Posteraro, M. Sanguinetti O0052Multi-centre clinical evaluation of a novel transcription-mediated amplification assay for SARS-CoV-2 molecular testing M. Fernández-Huerta* (Pamplona, Spain), P. Salmerón, Y. Hernández-Hermida, J. Niubó, L. Calatayud, M.A. Domínguez, T. Pumarola, C. Ardanuy, C. Andrés, A. Antón, J. Càmara O0053A 29-mRNA host response assay accurately identifies patients with COVID-19, detects bacterial co- and superinfections and predicts severity of illness at clinical presentation: a prospective multi-centre trial W. Bauer* (Berlin, Germany), S. Glaeser, J. Borchardt, A. Peric, J. Bialas, N. Galtung, O.L.I.E.S. Liesenfeld, L. Sun, L. May, S. Ott, S. Vesenbeckh O0054Clinical performance of direct RT-PCR testing of raw saliva for detection of SARS-CoV-2 in symptomatic and asymptomatic individuals N. Lucca* (Galway, Ireland), R. Castillo-Bravo, L. Lai, K. Marlborough, G. Brychkova, B. Smyth, P. Mckeown, J. Feenstra, C. Ulekleiv, M. Gandhi, C. Spillane O0055Longitudinal patterns of exhaled SARS-CoV-2 viral load collected by face-mask sampling and its relation to nasopharyngeal sampling viral load, clinical symptoms and household transmission in infected healthcare workers D. Pan* (Leicester, United Kingdom), C.M. Williams, J. Decker, E. Fletcher, S. Sze, S. Assadi, R. Haigh, B. Saleem, J. Nazareth, T. Clark, N.J. Garton, M. Pareek, M.R. Barer O0056Saliva as a sample type for cost-effective and scalable SARS-CoV-2 testing A. Wyllie* (New Haven, United States), O. Allicock, D. Yolda-Carr, C. Vogels, A. Watkins, M. Petrone, N. Grubaugh O0057The role of subgenomic RNA in causing inconclusive results from RT-PCR tests for COVID-19 N. Toppings* (Calgary, Canada), L. Oberding, Y.C. Lin, D. Evans, D. Pillai OS01308:30 - 10:30Hall K 2-Hour Oral Session Advances in prevention of urinary catheter and central line- associated bloodstream infections ChairsLisa Hall (Herston, Australia) Clare Rock (Baltimore, United States) O0058Impact of a national intervention on CLABSI and non-CLABSI rates in Israeli medical-surgical ICUs D. Ben-David* (Holon, Israel), A. Vaturi, E. Temkin, L. Wullfhart, E. Solter, Y. Carmeli, M. Schwaber O0059Combating multidrug-resistant catheter-related infections with cold plasma technology Z. Dor* (Ariel, Israel), Y. Bormashenko, J. Giller, J. Moran-Gilad, E. Bormashenko, S. Navon-Venezia O0060The accuracy of fully-automated surveillance algorithms for central venous catheter-related bloodstream infections in hospitalised patients S.D. Van Der Werff* (Stockholm, Sweden), M. Karmefors Idvall, H. Tanushi, P. Nauclér O0061Staphylococcus aureus nasal carriage and Staphylococcus aureusbloodstream infection among conventional haemodialysis patients in Thailand: a prospective multi-centre cohort study W. Nasomsong* (Bangkok, Thailand), T. Techasuphaboon, V. Vasiksin, N. Varothai, N. Rak Nai Sil O0062The impact of COVID-19 on central line- associated bloodstream infections (CLABSI) and device utilisation ratio (DUR) at a large healthcare system in Miami, FL A. Jimenez* (Miami, United States), A. Garcia, K. Sposato, J. Cardozo, O. Orozco, M. Ruiz, R. Mcdade, R. Williams, G. Sidimirova, J. Dobson, D. Roberts, K. Manzanillo, G. Rosello, R. Rosa, L. Abbo O0063Antiseptic barrier caps in central line-associated bloodstream infections: a systematic review and meta-analysis M. Leal Dos Santos* (Lisbon, Portugal), S. Tejada, R. Martínez-Reviejo, Y. Peña-Lopez, S. Blot, E. Alp, J. Rello O0064Surveillance programme for bloodstream infections in long-term central venous catheters in outpatient chemotherapy services D. Assis* (São Paulo, Brazil), M. Freire, F. Carlesse, P.C.P. Germano, J.M. Viroli, A.C. Turdo, B.Q. Rodrigues, A.L.P. Maciel, M.M. Viu, J.D.C. Belizario, P. Goncalves, E. Abdala, I. Boszczowski, A.S.S. Levin O0065Decrease in healthcare-associated infection methicillin-resistant Staphylococcus aureus bacteraemia using a prevention bundle audit tool with real-time feedback C. Carter* (Miami, United States), K.A. Sposato, M. Jimenez Hamann, L.M. Abbo O0066Pilot clinical trial: testing a diagnostic lozenge for impending urinary catheter blockage R. Heylen* (Bath, United Kingdom), T. Jenkins Saturday, 23 April 202238FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 O0067Bundle of interventions to accomplish 365 days without catheter-associated urinary tract infections (CAUTI) hospital-wide during the COVID-19 pandemic at a community hospital in Miami, FL A. Jimenez* (Miami, United States), K. Sposato, P.A. Anderson, V. Perez, J.V. Caprile, D. Diaz, M. Mann, L.M. Abbo OS01408:30 - 10:30Hall N 2-Hour Oral Session Soft tissue, bone and joint infections: a treatment update ChairsAnne Claude Cremieux (Paris, France) Andrej Trampuz (Berlin, Germany) O0068Community acquired skin and soft tissue infections in people who inject drugs compared to non-injection drug users R. Kivlehan* (Dublin, Ireland), N.R. Power, A. O’donnell, O. Hennigan, P. Mcgettrick, J.S. Lambert, G. Sheehan, A. Cotter, T. Mcginty, D. Morley, E. Muldoon, J. Woo O0069Experience with long-term linezolid use (>28 days) in bone and joint infections: safe and well- tolerated C.M. Veerman* (Nijmegen, Netherlands), D.S.C. Telgt, J.H.M. Goosen, P.J.C. Heesterbeek O0070Epidemiology and management of large joint septic arthritis: evolution over time during an eleven-year period at a referral centre P. Malosso* (Bologna, Italy), S. Tedeschi, E. Zamparini, N. Rossi, M. De Paolis, N. Maria Pia, P. Viale O0071Efficacy and safety of intravenous fosfomycin in patients with PJI: preliminary results from the PROOF study, a prospective multi-centre study S. Karbysheva* (Berlin, Germany), P. Morovic, D. Margaryan, L. Johannsen, A. Trampuz O0072Evaluation of the efficacy of ceftazidime- avibactam alone or in combinations in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis B. Davido* (Garches, France), A.C. Cremieux, A. Cara, I. Vaugier, L. Gatin, L. Noussair, L. Massias, F. Laurent, A. Saleh-Mghir O0073Time-trends in microbiological aetiology and resistance profile in diabetic foot osteomyelitis M. Mancheno-Losa* (Madrid, Spain), O. Robineau, E. Beltrand, D. Joulie, P. Patoz, N. Blondiaux, M. Cazaubiel, J. Lora-Tamayo, E. Senneville O0074Clinical experience of intravenous fosfomycin in the treatment of challenging infections D. Margaryan* (Berlin, Germany), S. Karbysheva, V. Dos Santos, A. Trampuz O0075Dalbavancin for indications other than skin and soft tissue infections: retrospective analysis of a large monocentric cohort S. Coladonato* (Pescara, Italy), F. Trave, E. Mazzotta, S. Ianniruberto, G. Parruti, G. Rapacchiale O0076Who returns to work after vertebral osteomyelitis? N. Jung* (Cologne, Germany), A. Yagdiran, J. Bredow, C. Otto-Lambertz, G. Mousabasha, N. Kernich, C. Weber, P. Eysel, J. Fischer O0077Septic arthritis of the knee: arthroscopy or arthrotomy? A comparative study J. Esteban* (Madrid, Spain), A. Martinez-Ulloa, M. Tovar-Bazaga, S. Gabardo-Calvo, J. Garcia- Cañete, A. Blanco-Garcia, E. Torrecilla-Sadaba, A. Auñon-Rubio ID CM SY01511:00 - 12:00Hall B Symposium Young Investigator Award for Research in CM and ID ChairsJon S. Friedland (London, United Kingdom) Annelies Zinkernagel (Zurich, Switzerland) S007811:00Can artificial intelligence and real-time monitoring support optimised antimicrobial use? Timothy Rawson (London, United Kingdom) S007911:30Epidemiology and clinical management of infections in patients with liver cirrhosis Michele Bartoletti (Bologna, Italy) PH SY01611:00 - 12:00Hall E Symposium COVID-19 beyond the clinic: the importance of public engagement ChairsKatharina Last (Homburg, Germany) Alvaro Pascual Hernandez (Seville, Spain) S008011:00Public engagement in COVID-19: pros and cons from the front line Yazdan Yazdanpanah (Paris, France) S008111:30Science, policy and social media in COVID-19 Isabella Eckerle (Geneva, Switzerland) Co-organised with: ESCMID Scientific Affairs Subcommittee (SAS) CM SY01711:00 - 12:00Hall I Symposium Pathogenic Escherichia coli: the emergence of cross- pathotypes from the genomic continuum ChairsTheresa J. Ochoa (Lima, Peru) Rosangela Tozzoli (Rome, Italy) S008211:00Escherichia coli pathotypes causing paediatric infection in low resource settings Inacio Mandomando (Maputo, Mozambique) Saturday, 23 April 2022Scientific Programme 39FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 S008311:30Redefining enteroaggregative Escherichia coli (EAEC): genomic characterisation of epidemiological EAEC strains Nadia Boisen (Copenhagen, Denmark) ID ME01811:00 - 12:00Hall J Meet-the-Expert Interactive paediatric cases M008411:00Julie Toubiana (Paris, France) M008511:30Susanna Esposito (Parma, Italy) Co-organised with: European Society of Paedriatic Infectious Diseases (ESPID) CM ME01911:00 - 12:00Hall K Meet-the-Expert How to apply Digital PCR in clinical microbiology M008611:00Jim Huggett (Teddington, United Kingdom) M008711:30Keith Jerome (Seattle, United States) OS02011:00 - 12:00Hall C 1-Hour Oral Session Novel insights into herpetic infections ChairsMatthijs Brouwer (Amsterdam, Netherlands) Gülsen Özkaya Sahin (Lund, Sweden) O0088Phenotypes of novel cytomegalovirus UL54 DNA polymerase mutations selected in clinically resistant transplant recipients M. Santos-Bravo* (Barcelona, Spain), N. Plault, M. Bodro, A. Moreno, A.B. Pérez-Jiménez, J. Torre- Cisneros, E. Vidal-Verdú, F. Cofán, C. Rodríguez- Rubio, S. Sánchez-Palomino, S. Alain, M.Á. Marcos O0089Human cytomegalovirus-specific T cell reconstitution and late-onset cytomegalovirus infection in haematopoietic stem cell transplant recipients following letermovir prophylaxis I. Cassaniti* (Pavia, Italy), E. Gabanti, O. Borsani, A.A. Colombo, F. Zavaglio, L. Binaschi, D. Caldera, R. Sciarra, G. Cassinelli, E.P. Alessandrino, P. Bernasconi, V.V. Ferretti, D. Lilleri, F. Baldanti O0090Time to first cytomegalovirus viraemia clearance in transplant recipients with refractory cytomegalovirus infection with or without resistance receiving maribavir versus investigator-assigned therapy: subgroup analyses of a phase III trial S. Alain* (Limoges, France), D. Florescu, D. Kumar, J. Wu, M. Fournier O0091Cytomegalovirus impact in B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy E. Marquez-Algaba* (Barcelona, Spain), B. Pernas, J. Esperalba, C. Carpio, I. Los-Arcos, G. Iacoboni, P. Barba, I. Ruiz-Camps O0092Comparison of viral and host transcriptomic profiles in patients with genital infections caused by herpes simplex viruses 1 and 2 S. Burrel* (Paris, France), D. Boutolleau, G. Gricourt, M. N’debi, V. Demontant, C. Rodriguez OS02111:00 - 12:00Hall F 1-Hour Oral Session Digital health applications for CM/ID ChairsSilvio Daniel Brugger (Zurich, Switzerland) Holger Rohde (Hamburg, Germany) O0093Learning a meaningful latent space representation for patient risk stratification: model development and validation for dengue B. Hernandez* (London, United Kingdom), O. Stiff, D.K. Ming, N.L. Vuong, N.M. Tuan, N.V.V. Chau, H.Q. Chanh, N.M. Nguyet, N.Q. Huy, P.K. Lam, D.T.H. Tam, D.T. Trung, H.T. Trieu, C.P. Simmons, B. Wills, A.H. Holmes, S. Yacoub, P. Georgiou O0094AmPHI-TIPS: risk stratification for pre-hospital patients M.L. Mogensen* (Aalborg, Denmark), L.M. Ward, A.L. Madsen, T.A. Lindskou, E.F. Christensen O0095Performance evaluation of machine-assisted interpretation of Gram stains from positive blood cultures C. Walter* (Heidelberg, Germany), C. Weissert, E. Gizewski, H. Mannsperger, I. Burckhardt, S. Zimmermann, O. Nolte O0096A machine learning approach to dengue diagnosis and the impact of seasonality in patients presenting with an acute febrile illness in Ho Chi Minh city, Vietnam D. Ming* (London, United Kingdom), N.M. Tuan, B. Hernandez, S. Sangkaew, N.L. Vuong, H.Q. Chanh, N.V.V. Chau, C.P. Simmons, B. Wills, P. Georgiou, A.H. Holmes, S. Yacoub O0097Combination of predictive classification algorithms, using automated training techniques and MALDI-TOF MS for capsular serotyping of Streptococcus pneumoniae J. Zintgraff* (Caba, Argentina), F. Rocca, M. Santos, D. Napoli, N. Sanchez Eluchans, C. Lara, M. Prieto Saturday, 23 April 2022Next >